Bruno K.L. Duarte , Isabella Valente , Afonso C. Vigorito , Francisco J.P. Aranha , Gislaine Oliveira-Duarte , Eliana C.M. Miranda , Irene Lorand-Metze , Katia B. Pagnano , Marcia Delamain , José F. Marques Junior , Silvia R. Brandalise , Márcio Nucci , Carmino A. De Souza
{"title":"巴西高剂量序贯化疗后自体造血干细胞移植治疗复发或难治性霍奇金淋巴瘤的经验","authors":"Bruno K.L. Duarte , Isabella Valente , Afonso C. Vigorito , Francisco J.P. Aranha , Gislaine Oliveira-Duarte , Eliana C.M. Miranda , Irene Lorand-Metze , Katia B. Pagnano , Marcia Delamain , José F. Marques Junior , Silvia R. Brandalise , Márcio Nucci , Carmino A. De Souza","doi":"10.3816/CLM.2009.n.088","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>We evaluate the effectiveness and toxicity of high-dose sequential chemotherapy (HDS) as salvage therapy in patients with advanced-stage Hodgkin lymphoma.</p></div><div><h3>Patients and Methods</h3><p>We performed a retrospective analysis on 77 patients receiving HDS between 1998 and 2006. Patients enrolled were in disease progression or relapsed disease, or did not achieve a complete remission after first-line treatment. HDS consisted of the sequential administration of cyclophosphamide and granulocyte colony-stimulating factor with stem cell harvesting, followed by methotrexate plus vincristine and etoposide.</p></div><div><h3>Results</h3><p>The majority of patients had stage III/IV (64%) and B symptoms (71.4%). Disease status improvement after HDS was observed in 24 of 57 patients (42%) previously in disease progression or relapse. HDS-related deaths occurred in 8 of 77 patients (10.4%). Four patients (5.2%) developed acute myeloid leukemia/myelodysplastic syndrome. Overall, disease-free and progression-free survival was 27%, 57%, and 25%, respectively.</p></div><div><h3>Conclusion</h3><p>Despite the treatment-related mortality, HDS is feasible, with satisfactory response rates, even in patients with poor prognosis.</p></div>","PeriodicalId":100272,"journal":{"name":"Clinical Lymphoma and Myeloma","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLM.2009.n.088","citationCount":"2","resultStr":"{\"title\":\"Brazilian Experience Using High-Dose Sequential Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma\",\"authors\":\"Bruno K.L. Duarte , Isabella Valente , Afonso C. Vigorito , Francisco J.P. Aranha , Gislaine Oliveira-Duarte , Eliana C.M. Miranda , Irene Lorand-Metze , Katia B. Pagnano , Marcia Delamain , José F. Marques Junior , Silvia R. Brandalise , Márcio Nucci , Carmino A. De Souza\",\"doi\":\"10.3816/CLM.2009.n.088\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>We evaluate the effectiveness and toxicity of high-dose sequential chemotherapy (HDS) as salvage therapy in patients with advanced-stage Hodgkin lymphoma.</p></div><div><h3>Patients and Methods</h3><p>We performed a retrospective analysis on 77 patients receiving HDS between 1998 and 2006. Patients enrolled were in disease progression or relapsed disease, or did not achieve a complete remission after first-line treatment. HDS consisted of the sequential administration of cyclophosphamide and granulocyte colony-stimulating factor with stem cell harvesting, followed by methotrexate plus vincristine and etoposide.</p></div><div><h3>Results</h3><p>The majority of patients had stage III/IV (64%) and B symptoms (71.4%). Disease status improvement after HDS was observed in 24 of 57 patients (42%) previously in disease progression or relapse. HDS-related deaths occurred in 8 of 77 patients (10.4%). Four patients (5.2%) developed acute myeloid leukemia/myelodysplastic syndrome. Overall, disease-free and progression-free survival was 27%, 57%, and 25%, respectively.</p></div><div><h3>Conclusion</h3><p>Despite the treatment-related mortality, HDS is feasible, with satisfactory response rates, even in patients with poor prognosis.</p></div>\",\"PeriodicalId\":100272,\"journal\":{\"name\":\"Clinical Lymphoma and Myeloma\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3816/CLM.2009.n.088\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma and Myeloma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1557919011700373\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma and Myeloma","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1557919011700373","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Brazilian Experience Using High-Dose Sequential Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
Purpose
We evaluate the effectiveness and toxicity of high-dose sequential chemotherapy (HDS) as salvage therapy in patients with advanced-stage Hodgkin lymphoma.
Patients and Methods
We performed a retrospective analysis on 77 patients receiving HDS between 1998 and 2006. Patients enrolled were in disease progression or relapsed disease, or did not achieve a complete remission after first-line treatment. HDS consisted of the sequential administration of cyclophosphamide and granulocyte colony-stimulating factor with stem cell harvesting, followed by methotrexate plus vincristine and etoposide.
Results
The majority of patients had stage III/IV (64%) and B symptoms (71.4%). Disease status improvement after HDS was observed in 24 of 57 patients (42%) previously in disease progression or relapse. HDS-related deaths occurred in 8 of 77 patients (10.4%). Four patients (5.2%) developed acute myeloid leukemia/myelodysplastic syndrome. Overall, disease-free and progression-free survival was 27%, 57%, and 25%, respectively.
Conclusion
Despite the treatment-related mortality, HDS is feasible, with satisfactory response rates, even in patients with poor prognosis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
